{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T12:32:55Z","timestamp":1724416375090},"reference-count":12,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Jpn. Soc. Intern. Med","J. Jpn. Soc. Intern. Med."],"published-print":{"date-parts":[[2014]]},"DOI":"10.2169\/naika.103.753","type":"journal-article","created":{"date-parts":[[2015,3,9]],"date-time":"2015-03-09T18:07:49Z","timestamp":1425924469000},"page":"753-759","source":"Crossref","is-referenced-by-count":2,"title":["The Prospects of Novel Anti-obesity Drugs"],"prefix":"10.2169","volume":"103","author":[{"given":"Hiroaki","family":"Ueno","sequence":"first","affiliation":[{"name":"Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamitsu","family":"Nakazato","sequence":"additional","affiliation":[{"name":"Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"2) Inoue S, et al: Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan. Am J Clin Nutr 55: 199S-202S, 1992.","DOI":"10.1093\/ajcn\/55.1.199s"},{"key":"2","unstructured":"3) Suplicy H, et al: A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. Int J Obes: doi: 10.1038\/ijo.2013.1225, 2013."},{"key":"3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","volume":"27","author":"JS Torgerson","year":"2004","unstructured":"4) Torgerson JS, et al: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27: 155-161, 2004.","journal-title":"Diabetes Care","ISSN":"http:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"4","doi-asserted-by":"crossref","unstructured":"5) Kopelman P, et al: Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity 18: 108-115, 2010.","DOI":"10.1038\/oby.2009.155"},{"key":"5","doi-asserted-by":"crossref","unstructured":"6) O'Neil PM, et al: Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity 20: 1426-1436, 2012.","DOI":"10.1038\/oby.2012.66"},{"key":"6","doi-asserted-by":"crossref","unstructured":"7) Chan EW, et al: Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev 14: 383-392, 2013.","DOI":"10.1111\/obr.12015"},{"key":"7","doi-asserted-by":"crossref","unstructured":"8) Garvey WT, et al: Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL):a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 95: 297-308, 2012.","DOI":"10.3945\/ajcn.111.024927"},{"key":"8","doi-asserted-by":"crossref","unstructured":"9) Astrup A, et al: Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374: 1606-1616, 2009.","DOI":"10.1016\/S0140-6736(09)61375-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"10) Lean ME, et al: Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes 2013.","DOI":"10.1038\/ijo.2013.149"},{"key":"10","doi-asserted-by":"crossref","unstructured":"11) Vilsboll T, et al: Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 344: d7771, 2012.","DOI":"10.1136\/bmj.d7771"},{"key":"11","doi-asserted-by":"crossref","unstructured":"12) Wysham C, et al: Once weekly exenatide: efficacy, tolerability and place in therapy. Diabetes Obes Metab 15: 871-881, 2013.","DOI":"10.1111\/dom.12084"},{"key":"12","doi-asserted-by":"crossref","unstructured":"13) Nakamura K, et al: Medical costs of obese Japanese: a 10-year follow-up study of National Health Insurance in Shiga, Japan. Eur J Public Health 17: 424-429, 2007.","DOI":"10.1093\/eurpub\/ckl271"}],"container-title":["Nihon Naika Gakkai Zasshi"],"original-title":["\u65b0\u305f\u306b\u767b\u5834\u3059\u308b\u6297\u80a5\u6e80\u85ac\u306e\u52d5\u5411\u3068\u5c55\u671b"],"language":"en","deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T16:21:10Z","timestamp":1566404470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/103\/3\/103_753\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2169\/naika.103.753","relation":{},"ISSN":["0021-5384","1883-2083"],"issn-type":[{"value":"0021-5384","type":"print"},{"value":"1883-2083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}